Sort by:
Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
Phase 2
Completed
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 95
- Registration Number
- NCT00088218
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 224
- Registration Number
- NCT00079482
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Mayo-Scottsdale, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
- Interventions
- Drug: AG-013736 (Axitinib)
- First Posted Date
- 2003-10-13
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00071006
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
Phase 2
Completed
- Conditions
- Myelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00067028
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00038805
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States